1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Resectable HER2-positive Breast Cancer: new trials by email Literature Review of Resectable HER2-positive Breast Cancer trials Research Report on Resectable HER2-positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer KN026, HB1801, Trastuzumab - Resectable HER2-positive Breast Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 1800 | 2026-03-06 | 2026-04-08 |
Carboplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Epirubicin (1) · Trastuzumab (1) · pertuzumab (1)
China (1)